Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Niacin Extended‐Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths having received final approval from the United States Food and Drug Administration (FDA) yesterday.
Lupin’s Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths are the AB‐rated generic equivalent of AbbVie Inc.’s Niaspan® Tablets 500 mg, 750 mg, 1000 mg and used with diet to reduce elevated TC, LDL‐C, Apo B and TG levels, and to increase HDL‐C in patients with primary hyperlipidemia and mixed dyslipidemia.
Niaspan® Tablets had annual U.S sales of approximately USD 1 billion (IMS MAT Dec, 2013). Commenting on the approval, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We are happy to launch this product having received approval from the FDA yesterday. The launch bears testimony to our commitment to serving our customers and patients by bringing high quality, affordable medicines to the market.”
Lupin’s Niacin Extended-Release Tablets USP, 500 mg, 750 mg, 1000 mg strengths are the AB‐rated generic equivalent of AbbVie Inc.’s Niaspan® Tablets 500 mg, 750 mg, 1000 mg and used with diet to reduce elevated TC, LDL‐C, Apo B and TG levels, and to increase HDL‐C in patients with primary hyperlipidemia and mixed dyslipidemia.
Niaspan® Tablets had annual U.S sales of approximately USD 1 billion (IMS MAT Dec, 2013). Commenting on the approval, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We are happy to launch this product having received approval from the FDA yesterday. The launch bears testimony to our commitment to serving our customers and patients by bringing high quality, affordable medicines to the market.”
